Get started
Author

Claus‐Henning Köhne

Observed names: Claus-Henning Kohne, Claus-Henning Köhne, Claus-Henning Köhne, Kohne, Claus-Henning
Observed institutions: Goethe University Frankfurt, Uppsala University, Roswell Park Comprehensive Cancer Center, University of Vienna, Carl von Ossietzky Universität Oldenburg, University Medical Center Groningen, Memorial Sloan Kettering Cancer Center, Merck KGaA, Darmstadt (Germany), University of Groningen, Universität Ulm, Max Delbrück Center, University Hospital Bonn, Kantonsspital St. Gallen, Cancer Research UK, Institut Gustave Roussy, Erasmus MC, University Hospital Heidelberg, Centre Hospitalier Universitaire Vaudois, University Hospital of Basel, Christian-Albrechts-Universität zu Kiel, Medizinische Hochschule Hannover, Humboldt-Universität zu Berlin, Düsseldorf University Hospital, Ospedale regionale di Lugano, Städtisches Klinikum Karlsruhe, Universitätsklinikum des Saarlandes, Hôpital Européen Georges-Pompidou, University Medical Center Hamburg-Eppendorf, Klinikum Oldenburg, University Hospital Schleswig-Holstein, Klinikum Braunschweig, Royal Marsden Hospital, Hôpital Ambroise-Paré, Swiss Group For Clinical Cancer Research, Velindre Cancer Centre, University Hospital Ulm, Kantonsspital Aarau, University Hospital Carl Gustav Carus, Hôpital Paul-Brousse, University of Rostock, Medical University of Vienna, Technische Universität Dresden, Charité - Universitätsmedizin Berlin, Medical Research Council
OpenAlex ID: A5109060535
Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial
2009 · Gunnar Folprecht, Thomas Gruenberger, et al. · The Lancet Oncology · 963
Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group
2007 · Richard Herrmann, György Bodoky, et al. · Journal of Clinical Oncology · 595
Towards a pan-European consensus on the treatment of patients with colorectal liver metastases
2006 · Eric Van Cutsem, Bernard Nordlinger, et al. · European Journal of Cancer · 587
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
2017 · Miguel Martin, Frankie A Holmes, et al. · The Lancet Oncology · 585
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
2012 · Carsten Bokemeyer, Eric Van Cutsem, et al. · European Journal of Cancer · 585
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
2010 · Sabine Kayser, Konstanze Döhner, et al. · Blood · 486
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer
2021 · Emmanouil Fokas, Anke Schlenska-Lange, et al. · JAMA Oncology · 361
Clinical, Molecular, and Prognostic Significance of WHO Type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and Various Other 3q Abnormalities in Acute Myeloid Leukemia
2010 · Sanne Lugthart, Stefan Gröschel, et al. · Journal of Clinical Oncology · 256
PDF
Never Too Old? Age Should Not Be a Barrier to Enrollment in Cancer Clinical Trials
2005 · Matti S. Aapro, Claus-Henning Köhne, et al. · The Oncologist · 244
PDF
Irinotecan/Fluorouracil Combination in First-Line Therapy of Older and Younger Patients With Metastatic Colorectal Cancer: Combined Analysis of 2,691 Patients in Randomized Controlled Trials
2008 · Gunnar Folprecht, Matthew T. Seymour, et al. · Journal of Clinical Oncology · 228
PDF
Secondary genetic lesions in acute myeloid leukemia with inv(16) or t(16;16): a study of the German-Austrian AML Study Group (AMLSG)
2012 · Peter Paschka, Juan Du, et al. · Blood · 185
TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group
2012 · Verena I. Gaidzik, Peter Paschka, et al. · Journal of Clinical Oncology · 185
PDF
Analysis of the p53/BAX Pathway in Colorectal Cancer: Low BAX Is a Negative Prognostic Factor in Patients With Resected Liver Metastases
1999 · Isrid Sturm, Claus-Henning Köhne, et al. · Journal of Clinical Oncology · 173
Monosomal karyotype in adult acute myeloid leukemia: prognostic impact and outcome after different treatment strategies
2011 · Sabine Kayser, Manuela Zucknick, et al. · Blood · 151
PDF
Does a patient’s self-reported health-related quality of life predict survival beyond key biomedical data in advanced colorectal cancer?
2005 · Fabio Efficace, Andrew Bottomley, et al. · European Journal of Cancer · 143
Chemotherapy in Elderly Patients with Colorectal Cancer
2008 · Claus-Henning Köhne, Gunnar Folprecht, et al. · The Oncologist · 109
PDF
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group
2008 · Eric Van Cutsem, Cornelius Van de Velde, et al. · European Journal of Cancer · 100
Treatment outcome according to tumor ERCC1 expression status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.
2013 · Carsten Bokemeyer, Claus-Henning Köhne, et al. · Journal of Clinical Oncology · 94
Chemotherapy with Targeted Agents for the Treatment of Metastatic Colorectal Cancer
2009 · Claus-Henning Köhne, Heinz-Josef Lenz · The Oncologist · 90
PDF
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus Paper
2020 · Bernhard Wörmann, Carsten Bokemeyer, et al. · Oncology Research and Treatment · 87
PDF
Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients
2014 · Michela Tassara, Konstanze Döhner, et al. · Blood · 83
Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer
1999 · Udo Vanhoefer, Andreas Harstrick, et al. · Journal of Clinical Oncology · 83
Impact of unbalanced minor route versus major route karyotypes at diagnosis on prognosis of CML
2015 · for the SAKK and the German CML Study Group, Alice Fabarius, et al. · Annals of Hematology · 81
First-line panitumumab plus irinotecan/5-fluorouracil/leucovorin treatment in patients with metastatic colorectal cancer
2011 · Claus-Henning Köhne, Ralf Hofheinz, et al. · Journal of Cancer Research and Clinical Oncology · 80
Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells
2005 · Jana Babatz, Christoph Röllig, et al. · Cancer Immunology Immunotherapy · 69
Works count: 133
Citation count: 7,792
H-index: 36
I10-index: 57
Year
Topic
Type